DaVita Stock Down Despite Q2 Earnings Beat, Gross Margin Expands

DaVita Inc. (DVA) reported strong second-quarter 2025 results, with adjusted EPS of $2.95, up 13.9% year-over-year and beating estimates by 9.3%, alongside revenue of $3.38 billion, a 6.1% increase that also topped consensus. Despite these top and bottom-line beats and a 31 basis point expansion in gross margin to 33.1%, the company's stock plunged nearly 10.1% following the announcement, likely influenced by a 36 basis point contraction in adjusted operating margin to 20.9% and a year-over-year decline in normalized non-acquired treatments.

Analysis

DaVita Inc. (DVA) presented a contradictory Q2 2025 earnings report, where strong headline figures were overshadowed by concerning underlying trends, triggering a 10.1% decline in its share price. The company surpassed consensus estimates with a 6.1% year-over-year revenue increase to $3.38 billion and a 13.9% rise in adjusted EPS to $2.95. This performance was supported by a 3.7% increase in revenue per treatment and a notable 37.4% growth in its 'Other revenues' segment, contributing to a 31 basis point expansion in gross margin to 33.1%. However, the market's negative reaction appears driven by a 36 basis point contraction in the adjusted operating margin to 20.9%, fueled by a 12.2% climb in general and administrative expenses. More critically, normalized non-acquired treatment volume, a key organic growth indicator, declined by 0.8% year-over-year. The balance sheet also showed signs of pressure, with total debt increasing to $10.26 billion and cumulative operating cash flow decreasing to $504.2 million from $664 million a year prior, even as the company executed a significant $446 million share repurchase. While DaVita reiterated its full-year EPS guidance, the combination of margin pressure, weakening organic treatment volume, and deteriorating cash flow has evidently spooked investors.

Key Decisions for Investors

• Investors should look beyond the headline earnings beat and scrutinize the contracting adjusted operating margin and the decline in normalized non-acquired treatments as primary indicators of operational pressure.
• The significant share repurchase of $446 million should be weighed against the concurrent rise in total debt to $10.26 billion and a year-over-year decline in operating cash flow, warranting caution regarding the sustainability of capital returns.
• Given the negative market reaction and fundamental concerns for DVA, it may be prudent to evaluate the relative strength of better-ranked industry peers like GEHC and WST, which demonstrated stronger quarterly results and analyst sentiment.
• Monitor future earnings calls for management's strategy to address rising administrative costs and reverse the negative trend in organic treatment volumes, as improvement in these areas is critical for a potential thesis change.